Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FREDERICK MIN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1366682429
CMS profile
107209
Location
SILVER SPRING, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$1,616.24

71 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FREDERICK MIN

NPI 1366682429 · CMS profile ID 107209

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SILVER SPRING, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1366682429?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FREDERICK MIN, NPI 1366682429, CMS profile ID 107209. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1366682429?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). FREDERICK MIN, NPI 1366682429, CMS profile ID 107209. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1366682429?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
FREDERICK MIN, NPI 1366682429, CMS profile ID 107209, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1366682429?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

71 matching records · $1,616.24 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 71 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–71 of 71.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Global Blood Therapeutics, Inc. $24.7405/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942699959 CMS
PharmaEssentia USA Corporation $24.6305/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941280979 CMS
PUMA BIOTECHNOLOGY, INC. $15.8404/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942288961 CMS
Bayer HealthCare Pharmaceuticals Inc. $25.1104/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930596047 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $29.4404/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887696731 CMS
Dendreon Pharmaceuticals LLC $22.7004/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943103447 CMS
Sobi, Inc $13.9403/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940375043 CMS
Lilly USA, LLC $21.6803/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918005013 CMS
Seagen Inc. $17.4803/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904119561 CMS
Gilead Sciences, Inc. $97.4903/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929561191 CMS
Janssen Pharmaceuticals, Inc $28.8703/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886393781 CMS
Novartis Pharmaceuticals Corporation $18.1203/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893978637 CMS
Takeda Pharmaceuticals U.S.A., Inc. $25.9803/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955737057 CMS
Seagen Inc. $21.5402/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904119563 CMS
AstraZeneca Pharmaceuticals LP $20.2002/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920257791 CMS
Celgene Corporation $18.4002/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932909719 CMS
Amgen Inc. $25.0002/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939322807 CMS
Incyte Corporation $23.9202/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943029565 CMS
Takeda Pharmaceuticals U.S.A., Inc. $21.2501/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955737051 CMS
MorphoSys, US Inc. $20.0001/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962540907 CMS
Seagen Inc. $16.8001/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904119531 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $359.96 18
PY2020 $1,235.87 13
PY2021 $765.66 35
PY2022 $1,616.24 71
PY2023 $4,282.19 86
PY2024 $2,664.34 102
PY2025 $2,397.56 99

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $136,045.72 20
PY2024 Principal investigator $332,041.44 21
PY2023 Principal investigator $223,547.42 25
PY2022 Principal investigator $231,296.70 26
PY2021 Principal investigator $179,224.79 22
PY2020 Principal investigator $21,386.00 2
PY2019 Principal investigator $14,874.78 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

20 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genmab U.S., Inc. $5,000.00 11/06/2025 Non-covered Recipient Entity
HOLY CROSS HOSPITAL/CANCER RESEARCH
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer No dispute reported 06/30/2026 1235930616
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/03/2025 Non-covered Recipient Entity
University of Kentucky Medical Center
DS8201-A-U305 No dispute reported 06/30/2026 1244555150
Principal investigator 1 PFIZER INC. $956.00 10/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY PA
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228716299
Principal investigator 1 Hexal AG $1,040.00 09/11/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
CGME751A12301 No dispute reported 06/30/2026 1186348690
Principal investigator 1 Hexal AG $1,560.00 09/11/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
CGME751A12301 No dispute reported 06/30/2026 1186348694
Principal investigator 1 Hexal AG $2,000.00 09/11/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
CGME751A12301 No dispute reported 06/30/2026 1186348696
Principal investigator 1 Hexal AG $208.00 09/11/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
CGME751A12301 No dispute reported 06/30/2026 1186348698
Principal investigator 1 Hexal AG $1,081.60 09/01/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
CGME751A12301 No dispute reported 06/30/2026 1186348686
Principal investigator 1 AstraZeneca Pharmaceuticals LP $34,728.00 08/06/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer ARTEMIDE-Lung04 No dispute reported 06/30/2026 1185540165
Principal investigator 1 PFIZER INC. $956.00 07/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY PA
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228716117
Principal investigator 1 Daiichi Sankyo Inc. $651.12 06/20/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-A-U305 No dispute reported 06/30/2026 1223346970
Principal investigator 1 PFIZER INC. $956.00 04/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY PA
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228716119
Principal investigator 1 AstraZeneca Pharmaceuticals LP $49,905.00 04/09/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
An open-label, randomized, multicenter, Phase 3 study to assess the efficacy and safety of Trastuzumab Deruxtecan as first-line treatment of unresectable, locally advanced or metastatic NSCLC harboring a HER2 exon 19 or 20 mutation (DESTINY-Lung04) No dispute reported 06/30/2026 1185540169
Principal investigator 1 AstraZeneca UK Limited $15,540.00 02/17/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
A Phase III,Open label,Randomised,Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations,and Whose Disease Has Progressed On or After Prior Anti PD 1 Therapy and Platinum based Chemotherapy LATIFY No dispute reported 06/30/2026 1185540163
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,550.00 01/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY LAUREL
A Phase III randomized study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib in patients with no germline BRCA mutation detected, platinum-resistant or refractory, high grade serous ovarian cancer No dispute reported 06/30/2026 1190307887
Principal investigator 1 PFIZER INC. $956.00 01/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY PA
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228716301
Principal investigator 1 AstraZeneca UK Limited $11,098.00 01/08/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
An Open label,Single arm, Phase two,Multinational,Multicentre Study to Assess the Efficacy and Safety of five Years of Osimertinib in Participants with Epidermal Growth Factor Receptor Mutation Positive Stage two 3B Nonsmall Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy TARGET No dispute reported 06/30/2026 1185540167
Principal investigator 1 Hexal AG $780.00 01/03/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
CGME751A12301 No dispute reported 06/30/2026 1186348668
Principal investigator 1 Hexal AG $1,040.00 01/03/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
CGME751A12301 No dispute reported 06/30/2026 1186348670
Principal investigator 1 Hexal AG $1,040.00 01/03/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
CGME751A12301 No dispute reported 06/30/2026 1186348802